NENCINI, FRANCESCA
 Distribuzione geografica
Continente #
NA - Nord America 1.675
EU - Europa 1.338
AS - Asia 305
AF - Africa 6
Totale 3.324
Nazione #
US - Stati Uniti d'America 1.665
PL - Polonia 438
RU - Federazione Russa 435
IT - Italia 151
IE - Irlanda 107
SE - Svezia 102
SG - Singapore 95
HK - Hong Kong 71
CN - Cina 66
JO - Giordania 33
GB - Regno Unito 30
FI - Finlandia 27
IN - India 22
DE - Germania 14
BE - Belgio 12
CA - Canada 10
TR - Turchia 9
VN - Vietnam 7
CH - Svizzera 6
CI - Costa d'Avorio 6
UA - Ucraina 5
FR - Francia 3
ES - Italia 2
LV - Lettonia 2
CZ - Repubblica Ceca 1
GE - Georgia 1
LT - Lituania 1
NL - Olanda 1
RO - Romania 1
TW - Taiwan 1
Totale 3.324
Città #
Warsaw 438
Santa Clara 327
Fairfield 175
Chandler 136
Ashburn 122
Dublin 107
Woodbridge 84
Cambridge 82
Singapore 80
Ann Arbor 73
Houston 69
Seattle 67
Wilmington 64
Hong Kong 48
Lawrence 37
Altamura 35
Beijing 34
Princeton 29
Buffalo 26
Florence 23
Mumbai 20
Jacksonville 19
Medford 19
Shanghai 19
Moscow 17
Boardman 16
New York 16
Boston 12
Brussels 11
Izmir 9
Los Angeles 9
Luni 9
Milan 9
London 8
Norwalk 8
Kent 7
Abidjan 6
Dong Ket 6
Toronto 6
Andover 5
Livorno 5
Washington 5
Falls Church 4
Helsinki 4
Ottawa 4
Phoenix 4
Lappeenranta 3
Ponti sul Mincio 3
Rome 3
San Diego 3
Yubileyny 3
Barcelona 2
Campi Bisenzio 2
Chester 2
Duncan 2
Frankfurt am Main 2
Genoa 2
Hillsboro 2
Imola 2
Lambeth 2
Laurel 2
Milzano 2
Monopoli 2
Palermo 2
Parma 2
Pesaro 2
Riga 2
Salerno 2
Sommacampagna 2
Torre del Greco 2
Varese 2
Zurich 2
Acton 1
Ambrolauri 1
Bari 1
Bologna 1
Bremen 1
Bucharest 1
Castelliri 1
Cologne 1
Hanoi 1
Hanover 1
Islington 1
Kilburn 1
Kolkata 1
Leawood 1
Macclesfield 1
Miaoli 1
Napoli 1
New Bedfont 1
Old Bridge 1
Padova 1
Prescot 1
Redmond 1
Redwood City 1
Rignano 1
San Mateo 1
Shenzhen 1
Tappahannock 1
Toulouse 1
Totale 2.398
Nome #
Treatment with 8-OH-modified adenine (TLR7 ligand)-allergen conjugates decreases T helper type 2-oriented murine airway inflammation 280
A novel allergen-adjuvant conjugate suitable for specific immunotherapy of respiratory allergy 276
Dermatophagoides pteronyssinus group 2 allergen bound to 8-OH modified adenine reduces the Th2-mediated airway inflammation without inducing a Th17 response and autoimmunity 247
Efficacy and safety of mepolizumab (Anti-Interleukin-5) treatment in Gleich's syndrome 158
The TLR7 Ligand 9-Benzyl-2-Butoxy-8-Hydroxy Adenine Inhibits IL-17 Response by Eliciting IL-10 and IL-10-Inducing Cytokines. 157
Skin testing and infliximab-specific antibodies detection as a combined strategy for preventing infusion reaction. 146
Assays and strategies for immunogenicity assessment of biological agents. 131
Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. 112
Manifestations of Antidrug Antibodies Response: Hypersensitivity and Infusion Reactions. 112
Drug-Specific Th2 Cells and IgE Antibodies in a Patient with Anaphylaxis to Rituximab 108
Modified adenine (9-benzyl-2-butoxy-8-hydroxyadenine) redirects Th2-mediated murine lung inflammation by triggering TLR7. 107
The percentage of patients achieving complete remission of urticaria increases with repeated courses of treatment 107
High proportion of inflammatory CD62Llow eosinophils in blood and nasal polyps of severe asthma patients 100
Modified adenine (9-benzyl-2-butoxy-8-hydroxyadenine) redirects Th2-mediated murine lung inflammation by triggering TLR7. 97
A novel nDer p2-conjugated TLR7 down-modulates Th2-associated lung inflammation by using a therapeutical protocol 93
Prompt Predicting of Early Clinical Deterioration of Moderate-to-Severe COVID-19 Patients: Usefulness of a Combined Score Using IL-6 in a Preliminary Study 91
Low-dose mepolizumab effectiveness in patients suffering from eosinophilic granulomatosis with polyangiitis 88
A modified adenine chemically coupled to allergen molecole redirects allergen-specific Th2 cells 79
Hydroxy-adenines as in vivo and in vitro immunomodulators of allergic responses 78
Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab. 78
Circulating T cells to infliximab are detectable mainly in treated patients developing anti-drug antibodies and hypersensitivity reactions 73
Etanercept inhibits the TNF-α driven shifting of Th17 towards non-classic Th1 phenotype in juvenile idiopathic arthritis. 71
Short and long-term effect of a novel nDer p2-conjugated TLR7 ligand in the prevention of allergic lung inflammation 71
The Kinetics of Antidrug Antibodies, Drug Levels, and Clinical Outcomes in Infliximab-Exposed Patients with Immune-Mediated Disorders 66
The anti-IgE monoclonal antibody omalizumab as adjuvant treatment in desensitization to carboplatin in patients with ovarian cancer 65
A novel antigen-conjugated TLR7 ligand regulates the lung inflammation and Th2-mediated response in a murine model of asthma 63
Immunogenicity of Biological Agents: Basic Knowledge and Clinical Implications 60
Long-term retention rate of mepolizumab treatment in severe asthma: a 36-months real-life experience 51
Drug-specific Treg cells are induced during desensitization procedure for rituximab and tocilizumab in patients with anaphylaxis 48
Modified (2-Butoxy-8-Hydroxy-9-Benzyl) adenine redirects type 2 murine lung inflammation by triggering TLR7 in dendritic cells 46
Comparison of ELISA with automated ECLIA for IL-6 determination in COVID-19 patients: An Italian real-life experience 32
Dietary Antioxidants and Natural Compounds in Preventing Thrombosis and Cardiovascular Disease 21
Post-translational modifications of fibrinogen: implications for clotting, fibrin structure and degradation 20
null 14
Fibrinogen Structural Changes and Their Potential Role in Endometriosis-Related Thrombosis 6
Totale 3.352
Categoria #
all - tutte 10.435
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.435


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020294 0 0 0 0 0 52 49 58 46 43 42 4
2020/2021283 36 23 8 42 14 43 11 19 26 26 20 15
2021/2022200 4 16 16 5 8 11 7 19 7 11 45 51
2022/2023589 48 124 29 34 40 95 73 36 81 5 13 11
2023/2024291 15 23 32 24 34 38 21 58 6 11 10 19
2024/20251.026 64 169 102 262 416 13 0 0 0 0 0 0
Totale 3.352